Skip to main content
Erschienen in: International Journal of Hematology 2/2008

01.03.2008 | Case Report

B-Lymphoid and myeloid lineages biphenotypic acute leukemia with t(8;21)(q22;q22)

verfasst von: Guangsheng He, Depei Wu, Aining Sun, Yongquan Xue, Zhengming Jin, Huiying Qiu, Xiaowen Tang, Miao Miao, Zhengzheng Fu, Xiao Ma, Xiuli Wang, Zixin Chen, Changgeng Ruan

Erschienen in: International Journal of Hematology | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

By analyzing the characteristics of morphology, immune phenotype, chromosome karyotype and clinical manifestations of six cases of B-lymphoid and myeloid lineages biphenotypic acute leukemia (BAL) with t(8;21)(q22;q22), a new subgroup of BAL was reported. Bone marrow eosinophilia (more than 5%) and pseudo-Chediak abnormalities were not found. Auer rods were also not identified in four of six cases. Immunophenotype revealed B-lymphoid and myeloid lineages positive, together with frequent and high expression of CD34 and CD33, and weak expression of HLA-DR. In addition to t(8;21) chromosomal translocation, deletion of Y chromosome and complex chromosome abnormalities were also found. Chemotherapy for myeloid and lymphoid leukemia simultaneously produced good response in the patients. BAL with t(8; 21)(q22; q22) might be a new subgroup of BAL, and it was suggested that the leukemia clone with t(8;21)(q22;q22) might have originated from an early phase of hematopoiesis, and AML1/ETO fusion gene might be related to differentiation of B lymphocyte.
Literatur
1.
Zurück zum Zitat Ferrara F, Vecchio LD. Acute Myeloid Leukemia with t(8;21)(q22;q22) /AML1/ETO: A distinct biological and clinical enity. Haematologica. 2002;87:306–19.PubMed Ferrara F, Vecchio LD. Acute Myeloid Leukemia with t(8;21)(q22;q22) /AML1/ETO: A distinct biological and clinical enity. Haematologica. 2002;87:306–19.PubMed
2.
Zurück zum Zitat Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, van’t Veer MB; European Group for the Immunological Characterization of Leukemia (EGIL). Proposals for the immunological classification of acute leukemias. Leukemia 1995;9:1783–6.PubMed Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, van’t Veer MB; European Group for the Immunological Characterization of Leukemia (EGIL). Proposals for the immunological classification of acute leukemias. Leukemia 1995;9:1783–6.PubMed
3.
Zurück zum Zitat Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med. 1985;103:620–5.CrossRefPubMed Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med. 1985;103:620–5.CrossRefPubMed
4.
Zurück zum Zitat Andrieu V, Radford-Weiss I, Troussard X, et al. Molecular detection of t(8,21)/AML1/ETO in AMLM1/M2: correlation with cytogenetics, morphology and immunophenotype. Br J Haematol. 1996;92:855–65.CrossRefPubMed Andrieu V, Radford-Weiss I, Troussard X, et al. Molecular detection of t(8,21)/AML1/ETO in AMLM1/M2: correlation with cytogenetics, morphology and immunophenotype. Br J Haematol. 1996;92:855–65.CrossRefPubMed
5.
Zurück zum Zitat Brunning RD, Matutes E, Borowitz MJ, et al Acute leukemia of ambiguous lineage. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, (eds). Pathology and genetics of tumors of the haematopoietic and lympholoid tissue. Lyon: IARC Press; 2001:106–7. Brunning RD, Matutes E, Borowitz MJ, et al Acute leukemia of ambiguous lineage. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, (eds). Pathology and genetics of tumors of the haematopoietic and lympholoid tissue. Lyon: IARC Press; 2001:106–7.
6.
Zurück zum Zitat Legrand O, Perrot J-Y, Simonin G, et al. Adult biphenotypic acute leukemia: an entity with poor prognosis which is related to unfavourable cytogenetics and P-glycoprotein over-expression. Br J Haematol. 1998:100:147–55.CrossRefPubMed Legrand O, Perrot J-Y, Simonin G, et al. Adult biphenotypic acute leukemia: an entity with poor prognosis which is related to unfavourable cytogenetics and P-glycoprotein over-expression. Br J Haematol. 1998:100:147–55.CrossRefPubMed
7.
Zurück zum Zitat Carbonell F, Swansbury J, Min T, et al. Cytogenetic findings in acute biphenotypic leukemia. Leukemia. 1996;10:1283–7.PubMed Carbonell F, Swansbury J, Min T, et al. Cytogenetic findings in acute biphenotypic leukemia. Leukemia. 1996;10:1283–7.PubMed
8.
Zurück zum Zitat Kozlov I, Beason K, Yu C, Hughson M. CD79a expression in acute myeloid leukemia t(8;21) and the importance of cytogenetics in the diagnosis of leukemias with immunophenotypic ambiguity. Cancer Genet Cytogenet. 2005;163:62–7.CrossRefPubMed Kozlov I, Beason K, Yu C, Hughson M. CD79a expression in acute myeloid leukemia t(8;21) and the importance of cytogenetics in the diagnosis of leukemias with immunophenotypic ambiguity. Cancer Genet Cytogenet. 2005;163:62–7.CrossRefPubMed
9.
Zurück zum Zitat Kuchenbauer F, Feuring-Buske M, Buske C. AML1-ETO needs a partner: new insights into the pathogenesis of t(8;21) leukemia. Cell cycle. 2005;4:1716–8.CrossRefPubMed Kuchenbauer F, Feuring-Buske M, Buske C. AML1-ETO needs a partner: new insights into the pathogenesis of t(8;21) leukemia. Cell cycle. 2005;4:1716–8.CrossRefPubMed
10.
Zurück zum Zitat Miyamoto T, Weissman IL, Akashi K. AML/ETO1-expressing non-leukemia stem cells in acute myelogenous leukemia with t(8;21) chromosomal translocation. Proc Natl Acad Sci USA. 2000;97:7521–6.CrossRefPubMedPubMedCentral Miyamoto T, Weissman IL, Akashi K. AML/ETO1-expressing non-leukemia stem cells in acute myelogenous leukemia with t(8;21) chromosomal translocation. Proc Natl Acad Sci USA. 2000;97:7521–6.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Libermann TA, Pan Z, Akbarali Y, et al. AML1 (CBFalpha2) cooperates with B cell-specific activating protein (BSAP/PAX5) in activation of the B cell-specific BLK gene promoter. J Biol Chem. 1999;274:24671–6.CrossRefPubMed Libermann TA, Pan Z, Akbarali Y, et al. AML1 (CBFalpha2) cooperates with B cell-specific activating protein (BSAP/PAX5) in activation of the B cell-specific BLK gene promoter. J Biol Chem. 1999;274:24671–6.CrossRefPubMed
12.
Zurück zum Zitat Nutt SL, Heavey B, Rolink AG, Busslinger M. Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature. 1999;401:556–62.CrossRefPubMed Nutt SL, Heavey B, Rolink AG, Busslinger M. Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature. 1999;401:556–62.CrossRefPubMed
13.
Zurück zum Zitat Kozmik Z, Wang S, Dorfler P, Adams B, Busslinger M. The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP. Mol Cell Biol. 1992;12:2662–72.CrossRefPubMedPubMedCentral Kozmik Z, Wang S, Dorfler P, Adams B, Busslinger M. The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP. Mol Cell Biol. 1992;12:2662–72.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Nutt SL, Morrison AM, Dorfler P, Rolink A, Busslinger M. Identification of BSAP (Pax-5) target genes in early B-cell development by loss- and gain-of-function experiments. EMBO J. 1998;17:2319–33.CrossRefPubMedPubMedCentral Nutt SL, Morrison AM, Dorfler P, Rolink A, Busslinger M. Identification of BSAP (Pax-5) target genes in early B-cell development by loss- and gain-of-function experiments. EMBO J. 1998;17:2319–33.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Fitzsimmons D, Hodsdon W, Wheat W, Maira SM, Wasylyk B, Hagman J. Pax-5 (BSAP) recruits Ets proto-oncogene family proteins to form functional ternary complexes on a B-cell-specific promoter. Genes Dev. 1996;10:2198–211.CrossRefPubMed Fitzsimmons D, Hodsdon W, Wheat W, Maira SM, Wasylyk B, Hagman J. Pax-5 (BSAP) recruits Ets proto-oncogene family proteins to form functional ternary complexes on a B-cell-specific promoter. Genes Dev. 1996;10:2198–211.CrossRefPubMed
16.
Zurück zum Zitat Zwollo P, Desiderio S. Specific recognition of the blk promoter by the B-lymphoid transcription factor B-cell-specific activator protein. J Biol Chem. 1994;269:15310–7.PubMed Zwollo P, Desiderio S. Specific recognition of the blk promoter by the B-lymphoid transcription factor B-cell-specific activator protein. J Biol Chem. 1994;269:15310–7.PubMed
17.
Zurück zum Zitat Kishi H, Wei XC, Jin ZX, et al. Lineage-specific regulation of the murine RAG-2 promoter: GATA-3 in T cells and Pax-5 in B cells. Blood. 2000;95:3845–52.PubMed Kishi H, Wei XC, Jin ZX, et al. Lineage-specific regulation of the murine RAG-2 promoter: GATA-3 in T cells and Pax-5 in B cells. Blood. 2000;95:3845–52.PubMed
Metadaten
Titel
B-Lymphoid and myeloid lineages biphenotypic acute leukemia with t(8;21)(q22;q22)
verfasst von
Guangsheng He
Depei Wu
Aining Sun
Yongquan Xue
Zhengming Jin
Huiying Qiu
Xiaowen Tang
Miao Miao
Zhengzheng Fu
Xiao Ma
Xiuli Wang
Zixin Chen
Changgeng Ruan
Publikationsdatum
01.03.2008
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 2/2008
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-008-0029-z

Weitere Artikel der Ausgabe 2/2008

International Journal of Hematology 2/2008 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.